RVMD Stock Price | Revolution Medicines Inc P/E, Revenue, EPS, & Forecasts

Revolution Medicines Inc • RVMD

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Revolution Medicines Inc

Ticker

RVMD

Trading on

NASDAQ

ISIN

US76155X1000

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Mark A. Goldsmith M.D., Ph.D.

Headquarters

700 Saginaw Drive, Redwood City, CA, United States, 94063

Employees

809

Website

revmed.com

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Metrics

BasicAdvanced

Market cap

$15.4B

P/E ratio

EPS

-$5.19

Dividend Yield

0.00%

Beta

0.96

Forward P/E ratio

EBIDTA

$-1.03B

Ex dividend date

Price & volume

Market cap

$15.4B

Average daily volume

2.3M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

9,035.1

Price to book

9.64

Earnings

EPS

-$5.19

EPS estimate (current quarter)

-$1.41

EPS estimate (next quarter)

-$1.52

EBITDA

$-1.03B

Revenues (TTM)

$0.7M

Revenues per share (TTM)

$0.01

Technicals

Beta

0.96

52-week High

$79.82

52-week Low

$29.17

50-day moving average

$59.79

200-day moving average

$43.95

Short ratio

7.05

Short %

9.60%

Management effectiveness

ROE (TTM)

-60.76%

ROA (TTM)

-32.29%

Profit margin

0.00%

Gross profit margin

$-880M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-95.20%

Share stats

Outstanding Shares

193M

Float

174M

Insiders %

1.87%

Institutions %

102.29%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 12 analysts.

Average price target

$81.15

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.12

-$0.96

-16.12%

Q4 • 24Missed

-$1.13

-$0.75

-50.67%

Q1 • 25Missed

-$1.31

-$1.12

-16.96%

Q2 • 25Missed

-$1.61

-$1.41

-14.18%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-248M

-∞%

Q2 • 25

$0M

$-305M

-∞%

Q3 • 25

NaN%

23.17%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$2.43B

$564M

23.22%

Q2 • 25

$2.25B

$655M

29.09%

Q3 • 25

-7.31%

16.10%

25.26%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-222M

$34.3M

$257M

$-229M

Q2 • 25

$-207M

$24.8M

$-1.6M

$-211M

Q3 • 25

-6.51%

-27.50%

-100.62%

-8.09%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Revolution Medicines Inc share?

Revolution Medicines Inc shares are currently traded for undefined per share.

How many shares does Revolution Medicines Inc have?

Revolution Medicines Inc currently has 193M shares.

Does Revolution Medicines Inc pay dividends?

No, Revolution Medicines Inc doesn't pay dividends.

What is Revolution Medicines Inc 52 week high?

Revolution Medicines Inc 52 week high is $79.82.

What is Revolution Medicines Inc 52 week low?

Revolution Medicines Inc 52 week low is $29.17.

What is the 200-day moving average of Revolution Medicines Inc?

Revolution Medicines Inc 200-day moving average is $43.95.

Who is Revolution Medicines Inc CEO?

The CEO of Revolution Medicines Inc is Dr. Mark A. Goldsmith M.D., Ph.D..

How many employees Revolution Medicines Inc has?

Revolution Medicines Inc has 809 employees.

What is the market cap of Revolution Medicines Inc?

The market cap of Revolution Medicines Inc is $15.4B.

What is the P/E of Revolution Medicines Inc?

The current P/E of Revolution Medicines Inc is null.

What is the EPS of Revolution Medicines Inc?

The EPS of Revolution Medicines Inc is -$5.19.

What is the PEG Ratio of Revolution Medicines Inc?

The PEG Ratio of Revolution Medicines Inc is null.

What do analysts say about Revolution Medicines Inc?

According to the analysts Revolution Medicines Inc is considered a buy.